KR20130096055A - Composition comprising extract of hirudo nipponica whitman for inhibiting synthesis of melanin - Google Patents
Composition comprising extract of hirudo nipponica whitman for inhibiting synthesis of melanin Download PDFInfo
- Publication number
- KR20130096055A KR20130096055A KR1020120017568A KR20120017568A KR20130096055A KR 20130096055 A KR20130096055 A KR 20130096055A KR 1020120017568 A KR1020120017568 A KR 1020120017568A KR 20120017568 A KR20120017568 A KR 20120017568A KR 20130096055 A KR20130096055 A KR 20130096055A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- water
- composition
- melanin
- group
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 239000000284 extract Substances 0.000 title claims abstract description 62
- 230000002401 inhibitory effect Effects 0.000 title claims abstract description 37
- 230000008099 melanin synthesis Effects 0.000 title claims description 25
- 241000237903 Hirudo Species 0.000 title abstract description 12
- 239000000401 methanolic extract Substances 0.000 claims abstract description 46
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 36
- 239000000469 ethanolic extract Substances 0.000 claims abstract description 20
- 239000002537 cosmetic Substances 0.000 claims abstract description 19
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 15
- 201000010099 disease Diseases 0.000 claims abstract description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 230000002087 whitening effect Effects 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 66
- 235000013305 food Nutrition 0.000 claims description 16
- 239000000243 solution Substances 0.000 claims description 14
- 238000004519 manufacturing process Methods 0.000 claims description 12
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 239000002778 food additive Substances 0.000 claims description 9
- 235000013373 food additive Nutrition 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 239000000725 suspension Substances 0.000 claims description 4
- 239000003921 oil Substances 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 235000015110 jellies Nutrition 0.000 claims description 2
- 239000008274 jelly Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 239000001993 wax Substances 0.000 claims description 2
- 102000003425 Tyrosinase Human genes 0.000 abstract description 30
- 108060008724 Tyrosinase Proteins 0.000 abstract description 30
- 230000003061 melanogenesis Effects 0.000 abstract description 4
- 230000015572 biosynthetic process Effects 0.000 abstract description 2
- 230000004913 activation Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 52
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 29
- 230000000694 effects Effects 0.000 description 20
- 201000001441 melanoma Diseases 0.000 description 20
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 16
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 16
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 11
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 11
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 230000002292 Radical scavenging effect Effects 0.000 description 9
- 230000003013 cytotoxicity Effects 0.000 description 9
- 231100000135 cytotoxicity Toxicity 0.000 description 9
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000002835 absorbance Methods 0.000 description 8
- 229960000271 arbutin Drugs 0.000 description 8
- LNTHITQWFMADLM-UHFFFAOYSA-N gallic acid Chemical compound OC(=O)C1=CC(O)=C(O)C(O)=C1 LNTHITQWFMADLM-UHFFFAOYSA-N 0.000 description 8
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 8
- 238000000605 extraction Methods 0.000 description 7
- 230000036564 melanin content Effects 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 210000004940 nucleus Anatomy 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000003833 cell viability Effects 0.000 description 5
- 238000002843 lactate dehydrogenase assay Methods 0.000 description 5
- 210000003491 skin Anatomy 0.000 description 5
- PRDFBSVERLRRMY-UHFFFAOYSA-N 2'-(4-ethoxyphenyl)-5-(4-methylpiperazin-1-yl)-2,5'-bibenzimidazole Chemical compound C1=CC(OCC)=CC=C1C1=NC2=CC=C(C=3NC4=CC(=CC=C4N=3)N3CCN(C)CC3)C=C2N1 PRDFBSVERLRRMY-UHFFFAOYSA-N 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 4
- 238000003222 MTT reduction assay Methods 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical class [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 229940074391 gallic acid Drugs 0.000 description 4
- 235000004515 gallic acid Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 230000004660 morphological change Effects 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000000049 pigment Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000008213 purified water Substances 0.000 description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 208000012641 Pigmentation disease Diseases 0.000 description 3
- 208000000453 Skin Neoplasms Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 210000002752 melanocyte Anatomy 0.000 description 3
- 230000000877 morphologic effect Effects 0.000 description 3
- 231100001083 no cytotoxicity Toxicity 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 230000019612 pigmentation Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 201000000849 skin cancer Diseases 0.000 description 3
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000218671 Ephedra Species 0.000 description 2
- 206010015150 Erythema Diseases 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 210000003855 cell nucleus Anatomy 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000005016 dendritic process Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 210000002780 melanosome Anatomy 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000012089 stop solution Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- VIYKYVYAKVNDPS-HKGPVOKGSA-N (2s)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 VIYKYVYAKVNDPS-HKGPVOKGSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- SPSPIUSUWPLVKD-UHFFFAOYSA-N 2,3-dibutyl-6-methylphenol Chemical compound CCCCC1=CC=C(C)C(O)=C1CCCC SPSPIUSUWPLVKD-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 1
- 235000004866 D-panthenol Nutrition 0.000 description 1
- 239000011703 D-panthenol Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- AHMIDUVKSGCHAU-UHFFFAOYSA-N Dopaquinone Natural products OC(=O)C(N)CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-UHFFFAOYSA-N 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 238000010867 Hoechst staining Methods 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- AHMIDUVKSGCHAU-LURJTMIESA-N L-dopaquinone Chemical compound [O-]C(=O)[C@@H]([NH3+])CC1=CC(=O)C(=O)C=C1 AHMIDUVKSGCHAU-LURJTMIESA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 241000258623 Whitmania pigra Species 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- UDEWPOVQBGFNGE-UHFFFAOYSA-N benzoic acid n-propyl ester Natural products CCCOC(=O)C1=CC=CC=C1 UDEWPOVQBGFNGE-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 210000002390 cell membrane structure Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 229960003949 dexpanthenol Drugs 0.000 description 1
- 238000002845 discoloration Methods 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- NPUOZEMYDHAAMG-UHFFFAOYSA-N hexamagnesium;trisilicate Chemical compound [Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-].[O-][Si]([O-])([O-])[O-] NPUOZEMYDHAAMG-UHFFFAOYSA-N 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- OLXYLDUSSBULGU-UHFFFAOYSA-N methyl pyridine-4-carboxylate Chemical compound COC(=O)C1=CC=NC=C1 OLXYLDUSSBULGU-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- 230000004792 oxidative damage Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 238000005502 peroxidation Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 210000004694 pigment cell Anatomy 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/98—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin
- A61K8/987—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution of animal origin of species other than mammals or birds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/204—Animal extracts
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 수질(Hirudo nipponica Whitman) 추출물의 티로시나제 저해활성 및 멜라닌 생성 저해활성, 항산화활성을 활용하는 화장료 조성물, 의약 조성물 및 식품 조성물에 관한 것이다.The present invention ( Hirudo) nipponica Whitman) relates to a cosmetic composition, a pharmaceutical composition and a food composition utilizing the tyrosinase inhibitory activity, melanin production inhibitory activity, antioxidant activity of the extract.
피부 표피를 구성하는 세포 중 멜라닌 세포는 태양광선의 노출에 의해 멜라닌 합성이 증가되고, 증가된 멜라닌은 외부자극으로부터 피부를 보호하는 이로운 작용을 하기도 하지만 홍반이나 색소침착, 피부의 흑화 현상, 피부노화, 피부암 유발, 멜라닌 전구물질들에 의한 독성으로 세포사멸을 촉진하는 등 인체에 유해하거나 미용학적인 문제를 야기한다. Among the cells that make up the skin epidermis, melanocytes increase melanin synthesis by exposure to sunlight, and the increased melanin protects the skin from external stimuli, but erythema, pigmentation, skin blackening, skin aging May cause skin cancer, toxicity by melanin precursors and promote cell death.
멜라닌은 멜라닌 소체(immature melanosome)에서 티로시나제(tyrosinase)를 주요 작용 효소로 하여, 아미노산인 티로신(tyrosine)이 3,4-dihydroxyphenylalanine (DOPA)과 DOPAquinone으로 변환되는 등의 과정을 거쳐 생성된다. 멜라닌 합성을 억제하기 위해 주요 효소인 티로시나제의 활성을 저해함으로써 멜라닌 합성 저해 및 미백효과를 유도할 수 있다[Kim 등, Korean J. Medicinal Crop . Sci . 16, 255-260, 2008].Melanin is produced through the process of converting the amino acid tyrosine into 3,4-dihydroxyphenylalanine (DOPA) and DOPAquinone by using tyrosinase as the main action enzyme in the immature melanosome. Inhibiting the activity of tyrosinase, a major enzyme to inhibit melanin synthesis, can induce melanin synthesis inhibition and whitening effect [Kim et al., Korean J. Medicinal Crop . Sci . 16 , 255-260, 2008].
멜라닌 생성 억제제가 개발되어 있기는 하지만 활성이 약하거나 색소세포의 변성 또는 치사를 일으키거나 세포 본래의 기능을 손상시키는 등의 부작용이 있는 경우도 있어, 멜라닌 생합성 저해활성을 가지며 부작용이 적은 새로운 약물의 개발이 필요하다.Although inhibitors of melanogenesis have been developed, there are some side effects such as weak activity, degeneration or lethality of pigment cells, or impaired cell intrinsic function. Need development
피부는 자외선 노출에 의해 생성된 활성산소종(reactive oxygen species, ROS)으로부터 산화적 손상을 받게 된다. 산소를 이용하는 모든 세포는 ROS를 생성하며 ROS는 지질과산화 반응을 일으키고 이로 인해 생성된 부산물들은 세포의 구성성분인 단백질과 DNA를 손상시켜 세포막 구조의 변화, 효소활성의 저하 및 세포의 변이를 초래한다. 또한 더 나아가 잔주름, 피부 건조증, 피부의 탄력감소, 내인성 노화에 비하여 굵고 깊은 주름, 햇빛에 노출된 피부 표피에 불규칙한 색소침착이 발생하며 일광흑자(solar lentigo) 등의 색소질환이 증가하게 된다. The skin is subjected to oxidative damage from reactive oxygen species (ROS) produced by UV exposure. All cells that use oxygen produce ROS, and ROS cause lipid peroxidation reactions, and the by-products damage proteins and DNA, which are components of cells, resulting in changes in cell membrane structure, decreased enzyme activity, and cell mutations. . In addition, compared to fine lines, dry skin, reduced skin elasticity, endogenous aging, irregular and thick pigmentation occurs on the skin epidermis exposed to sunlight, and pigment diseases such as solar lentigo increase.
본 발명은 세포독성이 적으며 티로시나제 저해활성, 멜라닌 생성 저해활성을 가지는 새로운 물질을 찾아 제공하는 것을 해결하고자 하는 과제로 한다. The present invention is to solve the problem to find and provide a new cytotoxic and less tyrosinase inhibitory activity, melanin production inhibitory activity.
상기 과제를 해결하기 위하여 본 발명은 수질추출물을 유효성분으로 포함하는 조성물을 제공한다.The present invention to solve the above problems provides a composition comprising a water extract as an active ingredient.
본 발명의 일구현예로서 수질추출물을 유효성분으로 포함하는 티로시나제 저해활성을 가지는 조성물을 제공한다.In one embodiment of the present invention provides a composition having a tyrosinase inhibitory activity comprising a water extract as an active ingredient.
본 발명의 다른 일구현예로서 수질추출물을 유효성분으로 포함하는 멜라닌 생성 저해활성을 가지는 조성물을 제공한다.As another embodiment of the present invention provides a composition having a melanin production inhibitory activity comprising a water extract as an active ingredient.
본 발명의 일구현예로서 수질추출물을 유효성분으로 포함하는 미백효과를 가지는 조성물을 제공한다.In one embodiment of the present invention provides a composition having a whitening effect comprising the water extract as an active ingredient.
본 발명의 일구현예로서 수질추출물을 유효성분으로 포함하는, 멜라닌 과다 생성으로 인한 질병의 예방, 개선, 치료용 조성물을 제공한다.In one embodiment of the present invention provides a composition for the prevention, improvement, treatment of diseases caused by the excessive production of melanin containing water extract as an active ingredient.
또한, 본 발명의 다른 일구현예로서 항산화활성을 가지는 조성물을 제공한다.In addition, another embodiment of the present invention provides a composition having antioxidant activity.
본 발명에서 제공하는 조성물에는 일구현예로서 화장료 조성물, 의약 조성물, 식품 조성물, 식품첨가제 조성물이 포함된다.The composition provided by the present invention includes a cosmetic composition, a pharmaceutical composition, a food composition, and a food additive composition as one embodiment.
본 특허출원을 통하여 제공되는 수질추출물을 포함하는 조성물은 티로시나제 저해활성, 멜라닌 생성 저해활성, 항산화활성을 가지며, B16-F10 멜라노마 세포주에 대한 세포독성이 없다. The composition comprising the water extract provided through the present patent application has tyrosinase inhibitory activity, melanin production inhibitory activity, antioxidant activity, and there is no cytotoxicity against B16-F10 melanoma cell line.
수질추출물을 포함하는 조성물은 안전한 티로시나제 저해, 멜라닌 생성 저해, 미백효과를 가지는 화장료 조성물, 의약 조성물, 식품 또는 식품첨가제 조성물로 사용될 수 있다.The composition containing the water extract may be used as a safe tyrosinase inhibition, melanin production inhibition, cosmetic composition having a whitening effect, a pharmaceutical composition, a food or food additive composition.
도 1은 수질추출물의 티로시나제 저해활성을 나타낸 그래프이다. 어세이 용액은 각 농도의 수질 메탄올 추출물 또는 에탄올 추출물 및 1500 units/mL 티로시나제, 1.5 mM 티로신을 포함한다. (A: 메탄올 추출물 투여군 B: 에탄올 추출물 투여군 Arb:알부틴 Arbutin). 어세이 혼합액은 37℃ 에서 15분간 반응시키고 490 nm에서 흡광도를 측정하였다. 각 실험값은 세 번의 실험결과의 평균±SD이다.
도 2 는 a-MSH-유도된 B16-F10 멜라노마 세포주에서의 수질 메탄올 추출물의 멜라닌 함량에 대한 효과를 보여준다. 세포는 24시간 동안 배양되었으며, 수질 메탄올 추출물을 처리한 후 1 μM of a-MSH 을 처리하여 96시간 배양되었다. (A: 세포 외 멜라닌 함량 B: 세포 내 멜라닌 함량). ***: p<0.001, *: p<0.005 (a-MSH 단독처리 대조군과 비교하여)
도 3은 수질추출물 처리에 의한 B16-F10 멜라노마 세포주의 생존도 (cell viability)를 보여준다. (A: MTT reduction assay, B: LDH release assay). 세포는 각 농도의 수질 메탄올 추출물을 처리하여 24시간 배양되었다. (A) MTT reductioin assay 후, MTT reduction rate (세 번의 실험값의 평균±SD)는 각 대조군의 생존율(survival rate)을 기준으로 계산되었다. (B) LDH release assay의 결과(세 번의 실험값의 평균±SD) 데이터는 비히클 투여군의 LDH 방출을 100%로 하여 표준화되었으며 대조군에 대한 % 값으로 표현되었다.
도 4는 수질 메탄올 추출물에 의한 B16-F10 멜라노마 세포주의 24시간 동안 모니터 된 형태학적 변화를 보여준다. 세포는 수질 메탄올 추출물을 24시간 동안 처리하였다 (A: 대조군, B: 5 μg/mL 처리군, C: 10 μg/mL 처리군, D: 50 μg/mL 처리군). 사진은 위상차현미경(phase-contrast microscope)을 사용하여 100배로 촬영하였다.
도 5는 수질 메탄올 추출물의 B16-F10 멜라노마 세포주에 대한 세포사멸효과를 관찰한 것이다. 세포는 수질 메탄올 추출물을 24시간 동안 처리하였다 (A: 대조군, B: 5 μg/mL 처리군, C: 10 μg/mL 처리군, D: 50 μg/mL 처리군). 고정된 세포를 hoechst 33342 (10 μM)로 염색하고 형광현미경(fluorescence microscope)을 사용하여 400배로 관찰하였다.1 is a graph showing the tyrosinase inhibitory activity of water extract. The assay solution contains water methanol extract or ethanol extract and 1500 units / mL tyrosinase, 1.5 mM tyrosine at each concentration. (A: methanol extract administration group B: ethanol extract administration group Arb: arbutin Arbutin). The assay mixture was reacted at 37 ° C. for 15 minutes and the absorbance was measured at 490 nm. Each experimental value is the mean ± SD of three experimental results.
FIG. 2 shows the effect on melanin content of water methanol extract in a-MSH-induced B16-F10 melanoma cell line. Cells were incubated for 24 hours, and treated with 1 M of a-MSH followed by 96 hours of treatment with aqueous methanol extract. (A: extracellular melanin content B: intracellular melanin content). ***: p <0.001, *: p <0.005 (compared to a-MSH alone control)
Figure 3 shows the viability (cell viability) of B16-F10 melanoma cell line by water extract treatment. (A: MTT reduction assay, B: LDH release assay). Cells were incubated for 24 hours with water concentration methanol extract of each concentration. (A) After the MTT reductioin assay, the MTT reduction rate (mean ± SD of three experimental values) was calculated based on the survival rate of each control group. (B) The results of the LDH release assay (mean ± SD of three experiments) were normalized to 100% LDH release in the vehicle-administered group and expressed as% values for the control group.
4 shows monitored morphological changes over 24 hours of B16-F10 melanoma cell line by water methanol extract. Cells were treated with water methanol extract for 24 hours (A: control group, B: 5 μg / mL treatment group, C: 10 μg / mL treatment group,
Figure 5 shows the effect of apoptosis on the B16-F10 melanoma cell line of the water methanol extract. Cells were treated with water methanol extract for 24 hours (A: control group, B: 5 μg / mL treatment group, C: 10 μg / mL treatment group,
이하, 본 발명을 상세히 설명한다.Hereinafter, the present invention will be described in detail.
본 발명의 발명자는 티로시나제 저해활성, 멜라닌 생성 저해활성을 가지며 세포독성이 적은 물질을 찾기 위하여 천연물들을 스크리닝한 결과, 수질추출물이 그러한 활성을 가진다는 것을 알아내었다.The inventors of the present invention screened natural products to find a substance having tyrosinase inhibitory activity, melanin production inhibitory activity and low cytotoxicity, and found that the water extract has such activity.
수질은 수질과(Hirudinidae)의 환형동물이라는 큰 분류 군에 속하며, 대표적으로 일본의질(Hirudo nipponica Whitman), 마황/관체금선질(Whitmania pigra Whitman) 및 유엽마황/다색질(Whitmania acranulata Whitman)의 건조체를 들 수 있다. Water quality belongs to the large group of hiraniidae annulus, and is typically Japanese Hirudo nipponica Whitman), ephedra / quality gold wire tube (Whitmania pigra Whitman) and Ephedra / Multicolor acranulata Whitman) dry body.
본 발명의 발명자들은 수질(Hirudo nipponica Whitman)의 메탄올 추출물 및 에탄올 추출물을 제조하여 각 추출물에 대한 생리활성을 검증한 결과, 수질의 에탄올 추출물(HNE)은 500 μg/mL 농도에서 티로시나제에 대하여 18.7% 저해활성을 가지며, 같은 농도에서 메탄올 추출물(HNM)은 28.6%의 저해활성을 가진다는 것을 확인하였다. B16-F10 멜라노마 세포주에서 멜라닌의 생성에 미치는 수질 메탄올 추출물의 영향을 조사한 결과, 최종 50 μg/mL의 농도에서 a-MSH 처리 대조군에 비해 멜라닌 함량이 약 50% 저해되었다는 것을 확인하였다.The inventors of the present invention water (Hirudo nipponica Methanol extracts and ethanol extracts of Whitman) were prepared and their physiological activities were verified. The water ethanol extracts (HNE) had 18.7% inhibitory activity against tyrosinase at 500 μg / mL and methanol at the same concentration. The extract (HNM) was confirmed to have an inhibitory activity of 28.6%. As a result of investigating the effect of the water methanol extract on the production of melanin in the B16-F10 melanoma cell line, it was confirmed that the melanin content was inhibited by about 50% compared to the a-MSH treated control at the final concentration of 50 μg / mL.
또한, 수질추출물의 항산화활성효과를 알아보기 위하여 총 페놀(phenol)성 물질 함량 및 DPPH 라디칼 소거능을 측정하였는데, 총 페놀 함량은 수질 메탄올 추출물(HNM)의 경우 165.5 μg/100 mg GAE, 수질 에탄올 추출물(HNE)은 147.4 μg/100 mg GAE인 것으로 분석되었다. DPPH 라디칼 소거능은 5 mg/mL에서 수질 에탄올 추출물(HNE)이 15.1%이었으며, 수질 메탄올 추출물(HNM) 3.3%로, 에탄올 추출물이 메탄올 추출물 보다 5배 이상 높은 활성을 보였다. In addition, the total phenolic substance content and DPPH radical scavenging ability were measured to investigate the antioxidant activity of water extracts. The total phenolic content was 165.5 μg / 100 mg GAE and water ethanol extract for water methanol extract (HNM). (HNE) was analyzed to be 147.4 μg / 100 mg GAE. DPPH radical scavenging activity was 15.1% in water ethanol extract (HNE) at 5 mg / mL, 3.3% in water methanol extract (HNM), and ethanol extract showed more than 5 times higher activity than methanol extract.
수질추출물의 B16-F10 멜라노마 세포주에 대한 세포독성을 측정하기 위해, 수질 메탄올 추출물을 사용하여 MTT reduction assay, LDH release assay, 세포의 형태학적 변화 관찰, hoechst 염색을 실시한 결과, 최종 50 μg/mL의 농도에서도 무처리 대조군과 상응하는 생존율을 가짐으로써 세포독성이 없다는 것을 확인하였다. In order to measure cytotoxicity of B16-F10 melanoma cell line of water extract, MTT reduction assay, LDH release assay, morphological changes of cells, and hoechst staining were performed using water methanol extract. It was confirmed that there is no cytotoxicity by having a survival rate corresponding to the untreated control even at the concentration of.
이와 같은 결과들은 수질추출물이 티로시나제 저해활성 및 멜라닌 생성 저해활성이 뛰어나며 항산화활성도 보유하고 있고 B16-F10 멜라노마 세포주에 대한 안전성이 우수하여, 독성으로 인한 유전자 변이, 불안정성 및 피부암 유발 등과 같은 부작용을 가지는 기존의 티로시나제 저해제에 대한 대체가 가능하다는 것을 시사한다. These results indicate that water extracts have excellent tyrosinase inhibitory activity, melanin production inhibitory activity, antioxidant activity and safety against B16-F10 melanoma cell line, and have side effects such as genetic mutation, instability and skin cancer caused by toxicity. This suggests that alternatives to existing tyrosinase inhibitors are possible.
따라서, 본 발명은 일구현예로서 수질추출물을 유효성분으로 포함하는 티로시나제 저해활성을 가지는 조성물을 제공한다.Accordingly, the present invention provides a composition having a tyrosinase inhibitory activity, including water extract as an active embodiment.
본 발명의 다른 일구현예로서 수질추출물을 유효성분으로 포함하는 멜라닌 생성 저해활성을 가지는 조성물을 제공한다.As another embodiment of the present invention provides a composition having a melanin production inhibitory activity comprising a water extract as an active ingredient.
본 발명의 일구현예로서 미백효과를 가지는 조성물을 제공한다.In one embodiment of the present invention provides a composition having a whitening effect.
본 발명의 다른 일구현예로서 수질추출물을 유효성분으로 포함하는 멜라닌 과다 생성으로 인한 질병의 예방, 개선, 치료용 조성물을 제공한다.Another embodiment of the present invention provides a composition for the prevention, improvement, treatment of diseases caused by the excessive production of melanin containing water extract as an active ingredient.
또한, 본 발명의 다른 일구현예로서 항산화활성을 가지는 조성물을 제공한다.In addition, another embodiment of the present invention provides a composition having antioxidant activity.
본 발명에서 제공하는 조성물에는 일구현예로서 화장료 조성물, 의약 조성물, 식품 조성물, 식품첨가제 조성물이 포함된다.The composition provided by the present invention includes a cosmetic composition, a pharmaceutical composition, a food composition, and a food additive composition as one embodiment.
수질추출물은 수질에 수질 중량의 약 1 내지 30배, 필요할 경우 그 이상의 용매를 첨가하여, 약 10oC 내지 100oC에서 약 1시간 내지 5일 동안 침지추출, 열탕추출, 환류순환, 압력추출 등의 방법으로 추출한 후, 여과(또는 원심분리 후 여과)하여 제조할 수 있으며, 감압농축, 동결건조 등의 방법을 추가로 사용할 수 있다. 상기 용매는 물, 탄소 수 1 내지 4의 저급알코올, 프로필렌글리콜, 초산에틸, 부틸렌글리콜, 에테르 및 클로로포름으로 구성된 군으로부터 선택된 하나 또는 그 이상의 혼합 용매인 것일 수 있다.Water extracts are added to the water quality by about 1 to 30 times the weight of water, and if necessary, more solvents are used, soaking, boiling water extraction, reflux circulation, and pressure extraction for about 1 to 5 days at about 10 o C to 100 o C After extraction by such a method, it can be prepared by filtration (or centrifugation and filtration), it may be further used a method such as concentrated under reduced pressure, lyophilization. The solvent may be one or more mixed solvents selected from the group consisting of water, lower alcohols having 1 to 4 carbon atoms, propylene glycol, ethyl acetate, butylene glycol, ether, and chloroform.
수질추출물은 액상, 분말, 또는 과립형태일 수 있으며, 이로 제한되지 않는다.The water extract may be in the form of liquid, powder, or granules, but is not limited thereto.
본 발명의 조성물은 의약용, 식품용, 화장용 등으로 사용가능하며 용도에 맞도록 어떠한 방법으로도 투여할 수 있다. 예를 들어, 비경구 또는 경구 투여가 가능하며, 투여 방법에 따라 적절한 제형으로 제조된다. 본 발명에 따른 조성물은 제형에 따라 통상의 방법에 의해 제조될 수 있다. The composition of the present invention can be used for medicine, food, cosmetics and the like and can be administered by any method to suit the purpose. For example, parenteral or oral administration is possible and is prepared in a suitable dosage form depending on the method of administration. The composition according to the invention can be prepared by conventional methods depending on the formulation.
수질추출물은 멜라닌 생성 저해활성이 있으며, 항산화활성을 가지고 있고, 세포독성이 낮으므로 화장료 조성물에 포함되어 사용이 가능하다. 특히 미백용 화장료 조성물로서 사용될 수 있다. Water extracts have melanin production inhibitory activity, have antioxidant activity, and have low cytotoxicity, so they can be used in cosmetic compositions. In particular it can be used as a cosmetic composition for whitening.
본 발명의 화장료 조성물은 총 중량에 대하여 수질추출물을 0.001 내지 90중량%, 바람직하게는 0.01 내지 70중량%를 포함할 수 있다. 또한 본 발명의 화장료는 수질추출물 외에 비타민, 펩티드, 다당, 지질 등을 더 포함할 수 있으며, 그 외 통상 화장료에 배합되는 유지성분, 보습제, 계면활성제, 안료, 자외선 흡수제, 방부제, 살균제, 산화방지제, 식물추출물, pH 조정제, 알코올, 향료, 정제수 등을 포함할 수 있으며, 이로 제한되지 않는다.Cosmetic composition of the present invention may comprise 0.001 to 90% by weight, preferably 0.01 to 70% by weight of the water extract relative to the total weight. In addition, the cosmetic of the present invention may further include vitamins, peptides, polysaccharides, lipids, etc., in addition to the water extract, and other fats and oils, moisturizers, surfactants, pigments, ultraviolet absorbers, preservatives, fungicides, antioxidants, etc. It may include, but is not limited to, plant extracts, pH adjusters, alcohols, flavorings, purified water, and the like.
본 발명의 화장료 조성물은 용액, 현탁액, 유탁액, 페이스트, 젤, 크림, 로션, 오일, 왁스, 파우더, 스프레이, 비누, 클린징, 팩, 파운데이션, 메이컵베이스 및 모발화장료로 구성된 군으로부터 선택된 제형일 수 있으며, 이로 제한되지 않는다.The cosmetic composition of the present invention may be in the form of a solution, suspension, emulsion, paste, gel, cream, lotion, oil, wax, powder, spray, soap, cleansing, , But is not limited to.
또한, 수질추출물은 티로시나제 과다 활성, 멜라닌 과다 생성으로 인한 질병의 예방 및 치료용 의약 조성물, 멜라닌 생성 저해용 의약 조성물 또는 항산화용 의약 조성물에 포함될 수 있다. In addition, the water extract may be included in the pharmaceutical composition for preventing and treating diseases caused by excessive activity of tyrosinase, excessive production of melanin, a pharmaceutical composition for inhibiting melanin production, or a pharmaceutical composition for antioxidant.
멜라닌 과다 생성으로 인한 질병으로는 홍반, 색소침착, 피부의 흑화 현상, 피부노화, 피부암 유발, 멜라닌 전구물질들에 의한 독성으로 세포사멸 등을 들 수 있으며, 이로 제한되지 않는다. 수질추출물은 이를 위하여 전신투여(예를 들어 경구 투여) 및 국소투여(예를 들어 피부도포) 방법을 각각 또는 동시에 사용할 수 있다.Diseases caused by the excessive production of melanin include erythema, pigmentation, skin blackening, skin aging, skin cancer, and cell death due to melanin precursors, but are not limited thereto. Water extracts can be used for this purpose, respectively or simultaneously, systemic (eg oral) and topical (eg skin).
본 발명에 있어서, 수질추출물은 조성물 전량 중, 0.0005~30중량%, 바람직하게는 0.01~10중량% 포함될 수 있으나, 목적에 따라 얼마든지 조절이 가능하다. 본 발명의 조성물의 최적 투여량은 연령, 개인차, 증상 등에 따라 적절히 결정되지만, 사람에게 투여하는 경우의 투여량은 통상 0.01~100 mg/kg, 바람직하게는 0.1~10 mg/kg이며, 이 양을 1일 1회 또는 수 회 나누어 투여할 수 있다.In the present invention, the water extract may be included in the total amount of the composition, 0.0005 to 30% by weight, preferably 0.01 to 10% by weight, but can be adjusted according to the purpose. The optimal dosage of the composition of the present invention is appropriately determined according to age, individual difference, symptoms, etc., but the dosage when administering to a human is usually 0.01-100 mg / kg, preferably 0.1-10 mg / kg, and this amount It can be administered once or several times a day.
본 발명의 조성물은 고형제, 용액제, 유제, 분산제, 미셀, 리포좀, 연고제 등의 형태로 사용될 수 있고, 경구 또는 비경구로 적용하기에 적합한 유기 또는 무기 담체 또는 부형제가 함께 포함될 수 있다. 본 발명의 조성물은, 예를 들면 정제, 산제, 펠렛제, 캡슐제, 환제, 좌약제, 용액제, 유제, 현탁제, 액제, 젤리, 주사제 및 사용하기에 적합한 임의의 기타 형태에 대해 일반적으로 비독성인 제약상 허용되는 담체와 함께 혼합될 수 있다. 사용 가능한 담체에는 고체상, 반고체상 또는 액체상의 포도당, 유당, 아라비아 고무, 젤라틴, 만니톨, 전분 페이스트, 삼규산 마그네슘염, 활석, 옥수수 전분, 각질 (角質), 콜로이드 성 실리카, 감자 전분, 우레아, 쇄 길이가 중간 정도인 트리글리세리드, 덱스트란 및 제제의 제조에 사용하기에 적합한 기타 담체가 포함된다. 또한, 보조제, 안정화제, 증점제, 착색제 및 향료제가 사용될 수 있다.The compositions of the present invention may be used in the form of solids, solutions, emulsions, dispersants, micelles, liposomes, ointments, and the like, and may include organic or inorganic carriers or excipients suitable for oral or parenteral application. The compositions of the present invention are generally for tablets, powders, pellets, capsules, pills, suppositories, solutions, emulsions, suspensions, solutions, jelly, injections and any other form suitable for use. It can be mixed with a nontoxic pharmaceutically acceptable carrier. Usable carriers include solid, semisolid or liquid glucose, lactose, gum arabic, gelatin, mannitol, starch paste, magnesium trisilicate salt, talc, corn starch, keratin, colloidal silica, potato starch, urea, chain Medium length triglycerides, dextran and other carriers suitable for use in the preparation of the formulations are included. In addition, auxiliaries, stabilizers, thickeners, colorants and flavoring agents can be used.
또한, 본 발명은 수질추출물을 유효성분으로 함유하는 티로시나제 활성 저해, 멜라닌 생성 저해, 항산화를 위한 식품 조성물 또는 식품첨가물 조성물을 제공한다. 또한 본 발명은 멜라닌 과다 생성으로 인한 질병의 예방 및 개선용 식품 조성물 또는 식품첨가물 조성물을 제공한다. 본 발명의 수질추출물을 포함하는 식품 조성물 또는 식품첨가물 조성물은 단독으로 또는 다른 식품 또는 식품 성분과 함께 통상적인 방법에 따라 적절하게 사용될 수 있다. 유효성분의 혼합량은 그의 사용 목적에 따라 적합하게 결정될 수 있다. 일반적으로, 수질추출물은 식품 또는 음료의 제조 시에 원료에 대하여 각각 0.0001 내지 30중량%, 바람직하게는 0.1 내지 10중량%의 양으로 첨가될 수 있으나, 첨가되는 양은 목적에 따라 얼마든지 조절이 가능하다. 상기 식품의 종류에 특별한 제한은 없으며, 예로는 육류, 소시지, 빵, 초콜릿, 캔디 류, 스낵 류, 과자 류, 피자, 라면, 기타 면 류, 껌 류, 아이스크림 류를 포함한 낙농제품, 각종 수프, 음료수, 차, 드링크제, 알코올 음료 및 비타민 복합제 등이 있다.The present invention also provides a food composition or food additive composition for inhibiting tyrosinase activity, inhibiting melanin production, and antioxidant containing water extract as an active ingredient. The present invention also provides a food composition or food additive composition for the prevention and improvement of diseases caused by melanin overproduction. The food composition or food additive composition comprising the water extract of the present invention may be suitably used alone or in combination with other food or food ingredients according to conventional methods. The mixing amount of the active ingredient can be appropriately determined depending on the purpose of use thereof. In general, the water extract may be added in an amount of 0.0001 to 30% by weight, preferably 0.1 to 10% by weight based on the raw materials in the manufacture of food or beverage, but the amount of the water extract can be adjusted as desired depending on the purpose Do. There is no particular limitation on the kind of the food. Examples of the food include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, dairy products including ice cream, Drinks, tea, drinks, alcoholic beverages, and vitamin complexes.
이하, 본 발명을 실시 예에 의하여 상세히 설명한다. 그러나 하기 실시 예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시 예에 의하여 한정되는 것은 아니다.Hereinafter, the present invention will be described in detail with reference to examples. However, the following examples are merely to illustrate the present invention, the content of the present invention is not limited by the following examples.
시약 및 실험 재료Reagents and Experimental Materials
본 실험에서 사용된 수질(Hirudo nipponica Whitman)은 2011년 7월 경남 산청군에 위치한 지리산대한당영농조합법인으로부터 제공받아 추출하여 실험에 사용하였다. DMEM medium, fetal bovine serum (FBS) 및 페니실린(penicillin), 스트렙토마이신(streptomycin) 등은 Invitrogen (Grand Island, NY, USA)에서 구입하여 사용하였다. 티로시나제(tyrosinase), 티로신(tyrosine), 알부틴(arbutin), folin-Ciocalteau's phenol, 2,2-diphenyl-1-picrylhydrazyl (DPPH), Na2CO3, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), a-melanocyte stimulating hormone (a-MSH)는 Sigma chemical Co. (st. Louis, Mo, USA)제품을 구입하여 사용하였다. Lactate dehydrogenase (LDH) release assay kit는 Wako Pure Chemical Industries, Ltd. (Osaka, Japan)로부터 구입하였다. 그 외 실험에 사용된 용매 및 시약은 모두 일급 이상의 등급을 사용하였다.Water quality used in this experiment ( Hirudo nipponica Whitman) was provided by Jirisan Daedang Agricultural Co., Ltd. located in Sancheong-gun, Gyeongnam, South Korea, and used for the experiment. DMEM medium, fetal bovine serum (FBS), penicillin (penicillin), streptomycin, and the like were purchased from Invitrogen (Grand Island, NY, USA). Tyrosinase, tyrosine, arbutin, folin-Ciocalteau's phenol, 2,2-diphenyl-1-picrylhydrazyl (DPPH), Na 2 CO 3 , 3- [4,5-dimethylthiazol-2-yl ] -2,5-diphenyl tetrazolium bromide (MTT), dimethyl sulfoxide (DMSO), a-melanocyte stimulating hormone (a-MSH) (st. Louis, Mo, USA) was purchased and used. Lactate dehydrogenase (LDH) release assay kit is available from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). The solvents and reagents used in the other experiments all used first grade or higher grades.
세포 배양Cell culture
본 실험에 사용된 색소 형성 세포주는 B16-F10 murine 멜라노마로 한국세포주은행(KCLB, Seoul)으로부터 분양 받아 사용하였다. 세포 배양을 위해 DMEM medium에 10% fetal bovine serum (FBS) 및 100 units/mL의 페니실린, 100 mg/mL의 스트렙토마이신을 첨가하여 사용하였고, 95%의 습도가 유지되는 37℃, 5% CO2 인큐베이터(MCO-18AIC, SANYO, Osaka, Japan)에서 배양하였다.Pigment forming cell line used in this experiment was used as a B16-F10 murine melanoma obtained from the Korea Cell Line Bank (KCLB, Seoul). For cell culture, 10% fetal bovine serum (FBS) and 100 units / mL penicillin and 100 mg / mL streptomycin were added to DMEM medium, and 37 ° C. and 5% CO 2 were maintained at 95% humidity. The cells were cultured in an incubator (MCO-18AIC, SANYO, Osaka, Japan).
통계처리Statistical processing
모든 자료처리는 SPSS-PC+ 통계 패키지를 사용하여 처리하였다. 각 항목에 따라 백분율과 평균치±표준편차(SD)를 구하고, 실험군 간의 평균값의 통계적 유의성은 추출용매에 따른 총 페놀 함량의 차이는 Student t-test에 의해 p<0.05 수준에서 유의성을 검증하였다. 추출용매 별 또는 각 농도 별 DPPH 라디칼 소거능의 차이와 티로시나제 저해활성, 세포생존율, 멜라닌 함량 비교는 one way ANOVA법으로 분산분석을 하였으며, 유의성 검정은 p<0.05 수준에서 Duncan's multiple range test로 실시하였다.All data processing was done using the SPSS-PC + statistical package. Percentage and mean ± standard deviation (SD) were calculated according to each item, and statistical significance of the mean value among the experimental groups was verified by the Student t-test for the difference in total phenol content according to the extraction solvent. Differences in DPPH radical scavenging activity, tyrosinase inhibitory activity, cell viability, and melanin content by extraction solvent or concentration were analyzed by variance analysis using one-way ANOVA method.
<실험 예 1> 시료의 추출물 제조Experimental Example 1 Preparation of Extract of Sample
수질 5 g에 각각 50 mL의 메탄올 또는 에탄올을 가하여 상온에서 3일 동안 정치시켜 추출한 후, 여과지(Advantec, Tokyo, Japan)로 여과하였다. 여과된 추출액은 회전감압농축기(EYELA N-1000, Tokyo, Japan)를 이용하여 40℃에서 감압 농축하여 추출물을 얻었다. 메탄올 추출물은 HNM, 에탄올 추출물은 HNE라고 명명하였다. 각각의 추출물은 티로시나제 억제활성, 멜라닌 생성 억제활성, 항산화활성, 세포독성 실험을 위하여 각각 메탄올과 에탄올에 녹여 적당한 농도로 희석하여 처리하였다.50 mL of methanol or ethanol was added to 5 g of water, and the mixture was left to stand at room temperature for 3 days, followed by extraction with a filter paper (Advantec, Tokyo, Japan). The filtered extract was concentrated under reduced pressure at 40 ℃ using a rotary pressure reducer (EYELA N-1000, Tokyo, Japan) to obtain an extract. The methanol extract was named HNM and the ethanol extract was named HNE. Each extract was dissolved in methanol and ethanol and diluted to appropriate concentrations for tyrosinase inhibitory activity, melanin inhibitory activity, antioxidant activity, and cytotoxicity experiments.
<실험 예 2> <Experimental Example 2> TyrosinaseTyrosinase 저해활성 측정 Measurement of inhibitory activity
멜라닌 색소 생성의 중요한 단계를 촉매하는 효소인 티로시나제 활성에 대한 수질추출물의 저해효과를 조사하기 위해 기존의 피부미백제인 알부틴(arbutin)과 수질추출물의 농도에 따른 티로시나제의 저해활성을 비교하였다. 수질 메탄올 추출물(HNM)과 수질 에탄올 추출물(HNE)의 in vitro mushroom tyrosinase 활성저해 능력을 알아보기 위해 96-well plate 의 각 well에 100 μL의 시료와 0.05 M sodium phosphate buffer (pH 6.8) 140 μL, 효소(1500 units/mL mushroom tyrosinase) 20 mL, 기질(1.5 mM tyrosine) 40 μL을 순서대로 첨가한 후 37℃에서 15분 동안 incubation한 다음 ELISA reader를 이용하여 490 nm에서 흡광도를 측정하였다. 대조군은 각각 메탄올과 에탄올 100 μL, 양성 대조군으로는 알부틴 1 mM을 사용하였다. In order to investigate the inhibitory effect of water extract on tyrosinase activity, an enzyme catalyzing an important step in the production of melanin pigment, we compared the inhibitory activity of tyrosinase according to the concentration of arbutin and water extract. Water Methanol Extract (HNM) and Water Ethanol Extract (HNE) in To determine the ability to inhibit in vitro mushroom tyrosinase activity, 100 μL of sample and 140 μL of 0.05 M sodium phosphate buffer (pH 6.8) were added to each well of a 96-well plate, 20 mL of enzyme (1500 units / mL mushroom tyrosinase), substrate (1.5). 40 μL of mM tyrosine was added sequentially, followed by incubation at 37 ° C. for 15 minutes, and then absorbance at 490 nm was measured using an ELISA reader. As a control, 100 μL of methanol and ethanol, respectively, and 1 mM of arbutin were used as a positive control.
수질추출물을 각각 10, 50, 100, 500 μg/mL의 농도로 처리하여 활성을 측정해본 결과, 티로시나제 활성이 수질 메탄올 추출물(HNM) 처리군은 각각 20.9, 23.6, 24.4, 28.6% 저해되었으며, 수질 에탄올 추출물(HNE) 처리군은 각각10.4, 11.0, 13.0, 18.7% 저해되어 농도 의존적이며 통계적으로 유의한 저해효과를 나타내었다. 수질 메탄올 추출물(HNM)이 수질 에탄올 추출물(HNE)보다 티로시나제 저해활성이 높았다(도 1A, B). 수질의 티로시나제 저해활성은 알부틴 1 mM에 비해 낮은 활성을 보이지만, 추출물인 상태를 감안한다면 충분히 높은 저해활성을 가지는 것으로 보인다.As a result of measuring the activity of water extracts at concentrations of 10, 50, 100 and 500 μg / mL, tyrosinase activity was inhibited by 20.9, 23.6, 24.4 and 28.6% in the water methanol extract (HNM), respectively. Ethanol extract (HNE) treatment group was inhibited by 10.4, 11.0, 13.0, 18.7%, respectively, showing a concentration-dependent and statistically significant inhibitory effect. Water methanol extract (HNM) was higher tyrosinase inhibitory activity than water ethanol extract (HNE) (Fig. 1A, B). Water quality tyrosinase inhibitory activity is lower than that of
<실험 예 3> 멜라닌 생성량 측정Experimental Example 3 Measurement of Melanin Production
B16-F10 멜라노마 세포주에 대한 수질 메탄올 추출물(HNM)의 멜라닌 생성 억제효과를 평가하기 위하여 세포주를 6-well plate에 5x104 cells/mL이 되도록 2 mL씩 첨가한 후 24시간 동안 배양하였다. 다음, 수질 메탄올 추출물(HNM)을 각각 10, 50 μg/mL의 농도로 처리하고 대조군은 1% 메탄올이 되도록 처리한 후 멜라닌 생성 유도제인 a-MSH 1 μM을 처리하고 96시간 동안 배양하여 멜라닌의 생성을 유도하여 세포 배양액과 세포 내 멜라닌의 생성량을 측정하였다. 배양한 세포를 0.25% trypsin-EDTA 용액을 처리하여 세포를 수확한 후 원심분리하고 cell pellet에 1 N NaOH를 넣고, 80℃에서 10분간 세포를 녹여 415 nm에서 흡광도를 측정하였다. In order to evaluate the melanin production inhibitory effect of the water methanol extract (HNM) on the B16-F10 melanoma cell line, the cell line was added to a 6-well plate 2 mL to 5x10 4 cells / mL and incubated for 24 hours. Next, the aqueous methanol extract (HNM) was treated at a concentration of 10 and 50 μg / mL, respectively, and the control group was treated with 1% methanol, and then treated with 1-M of a-MSH, a melanin production inducer, and incubated for 96 hours. Production was induced to measure the cell culture and the production of melanin in the cells. After culturing the cells treated with 0.25% trypsin-EDTA solution, the cells were harvested and centrifuged. 1 N NaOH was added to the cell pellet, and the cells were dissolved at 80 ° C. for 10 minutes and the absorbance was measured at 415 nm.
배양액 속의 멜라닌 함량을 측정한 결과, 무처리군을 100%로 하였을 때 a-MSH 처리군은 151%으로 나타나 a-MSH 처리로 멜라닌 생성 유도가 된 것을 확인할 수 있었고, 수질 메탄올 추출물(HNM)을 50 μg/mL의 농도로 처리 시 101.5%로 a-MSH 단독 처리군보다 멜라닌 생성량이 통계적으로 유의하게 감소하였으며 양성대조군인 알부틴 100 μM의 농도로 처리했을 때 보다 높은 억제율을 나타낸다는 것을 확인할 수 있었다(도 2A). As a result of measuring the melanin content in the culture medium, when the untreated group was 100%, the a-MSH treated group was found to be 151%, indicating that melanin production was induced by the a-MSH treatment, and the water methanol extract (HNM) was obtained. It was confirmed that melanin production was significantly lower than the a-MSH-treated group at 101.5% when treated at the concentration of 50 μg / mL, and showed higher inhibition rate when treated with 100 μM of arbutin, the positive control group. (FIG. 2A).
세포 내의 멜라닌의 생성량을 측정한 결과, 무처리군을 100%로 하였을 때 a-MSH 처리군은 147.4%였다. 수질 메탄올 추출물(HNM) 10 μg/mL처리군은 113.2%, 50 μg/mL처리군은 69.0%으로 유의하게 감소하여, 양성 대조군인 알부틴 100 μM의 농도 처리군(129.8%)보다 약 60% 가량 멜라닌 생성량을 더 저해한다는 것을 확인할 수 있었다(도 2B). 이는 하기의 세포독성 결과(실험 예 6 내지 9)을 고려할 때, 세포독성으로 인해 세포가 생육하지 못하여 멜라닌 생성량이 감소된 것이 아니며, 멜라닌 합성은 멜라닌 세포 내 티로시나제 활성에 비례하고 멜라닌 함량측정 결과는 티로시나제의 활성 억제효과와 경향이 같은 것으로 보아 수질추출물은 멜라닌화(melanogenesis)에 대한 방어효과가 있다고 할 수 있다.As a result of measuring the amount of melanin produced in the cells, the a-MSH treated group was 147.4% when the untreated group was 100%. Water Methanol Extract (HNM) significantly decreased to 113.2% in the 10 μg / mL treatment group and 69.0% in the 50 μg / mL treatment group, about 60% more than the 100% treatment of arbutin, the positive control group (129.8%). It was confirmed that further inhibit the melanin production (Fig. 2B). When considering the following cytotoxicity results (Experimental Examples 6 to 9), the cells did not grow due to cytotoxicity did not reduce melanin production, melanin synthesis is proportional to tyrosinase activity in melanocytes and melanin content measurement results In view of the same tendency to inhibit the activity of tyrosinase, water extract can be said to have a protective effect against melanogenesis.
<실험 예 4> 총 페놀성 물질 함량 측정Experimental Example 4 Measurement of Total Phenolic Material Content
항산화활성을 가지는 물질의 대부분이 페놀(phenol)을 함유하고 있으므로, 추출물 상태에서 페놀의 양을 측정함으로써 항산화활성 등의 생리활성 기능을 알 수 있다. 본 발명에서는 표준품으로 gallic acid를 선택하여 수질추출물에 들어있는 폴리페놀성 물질의 함량을 측정하였다. 추출된 각 페놀성 물질의 함량 측정은 Singleton과 Rossi의 방법[Park, S, N. Journal of Korean Industrial and Engineering Chemistry. 14(5), 657-665, 2003]을 실험에 맞게 변형하였다. 수질 메탄올 추출물(HNM)과 수질 에탄올 추출물(HNE) 200 μL에 1N-Folin-Ciocalteau reagent 200 μL를 첨가하여 3분 동안 실온에 방치하고 10% Na2CO3 200 μL를 첨가하여 암실에 1시간 방치한 후 13,400×g에서 5분 동안 원심 분리하여, 반응액을 690 nm에서 흡광도를 측정하였다. 표준검정곡선은 gallic acid를 사용하여 작성하였으며, 총 페놀의 함량은 표준검정곡선으로부터 계산하였다. Since most of the substances having antioxidant activity contain phenol, physiologically active functions such as antioxidant activity can be known by measuring the amount of phenol in the extract state. In the present invention, gallic acid was selected as a standard to measure the content of polyphenolic substances in water extracts. The content of each extracted phenolic substance was measured by Singleton and Rossi [Park, S, N. Journal of Korean Industrial and Engineering Chemistry. 14 (5) , 657-665, 2003] were adapted to the experiment. Allowed to stand in water methanol extract (HNM) and water ethanol extract (HNE) by the addition of 1N-Folin-
총 페놀 함량은 수질 메탄올 추출물(HNM) 100 mg을 기준으로 165.5 μg/100 mg GAE였으며, 수질 에탄올 추출물(HNE)은 147.4 μg/100 mg GAE였다(표 1). GAE는 gallic acid equivalents 를 의미한다. The total phenolic content was 165.5 μg / 100 mg GAE based on 100 mg of water methanol extract (HNM) and water ethanol extract (HNE) was 147.4 μg / 100 mg GAE (Table 1). GAE stands for gallic acid equivalents.
추출용매
Extraction solvent
HNM
HNM
HNE
HNE
165.5±23.17
165.5 ± 23.17
147.4±1.55
147.4 ± 1.55
aGAE: gallic acid equivalents a GAE: gallic acid equivalents
모든 결과의 수치는 세 번의 실험값의 평균±SD 임.The numerical values of all results are the mean ± SD of the three experimental values.
<실험 예 5> <Experimental Example 5> DPPHDPPH 라디칼Radical 소거능Scatters 측정 Measure
DPPH 라디칼 소거능(radical scavenging activity, RSA)은 항산화활성과 연관성이 높으며, 짙은 자색의 시약이 추출물을 통해 노란색으로 탈색되는 정도를 확인하여 항산화물질의 수소 공여능 정도를 알아보는 실험이다. 수질 메탄올 추출물(HNM)과 수질 에탄올 추출물(HNE)의 DPPH 라디칼 소거능을 알아보기 위해 Thitilerdecha등의 방법[Thitilertdecha, N. 등, Food science and Technol . 41, 2029-2035, 2008]을 실험에 맞게 변형하여 사용하였다. 추출한 수질시료 20 μL에 0.2 mM DPPH 용액 80 μL를 첨가하여 10초 동안 섞은 후 실온에서 10분간 방치 후 492 nm에서 흡광도를 측정하였다.DPPH radical scavenging activity (RSA) is highly related to antioxidant activity, and it is an experiment to check the degree of hydrogen donating ability of antioxidants by checking the degree of discoloration of the dark purple reagent through the extract. Thitilerdecha et al. [Thitilertdecha, N. et al., Food , Inc.] for the DPPH radical scavenging activity of water methanol extract (HNM) and water ethanol extract (HNE) science and Technol . 41 , 2029-2035, 2008] was used to modify the experiment. 80 μL of 0.2 mM DPPH solution was added to 20 μL of the extracted water sample, mixed for 10 seconds, and the absorbance was measured at 492 nm after standing at room temperature for 10 minutes.
수질추출물 각각 0.1, 0.5, 1, 5 mg/mL의 농도에서 측정한 결과, DPPH 라디칼 소거능이 수질 메탄올 추출물(HNM)은 각각 0.9, 1, 2.8, 3.3%이며, 수질 에탄올 추출물(HNE)은 각각 5.6, 7.5, 8.4, 15.1%로 농도 의존적이며 통계적으로 유의한 결과를 확인하였으며, 수질 에탄올 추출물(HNE)이 상대적으로 수질 메탄올 추출물(HNM)보다 DPPH radical 소거능이 높은 것을 확인 할 수 있었다(표 2). The water extracts were measured at concentrations of 0.1, 0.5, 1, and 5 mg / mL, respectively. The DPPH radical scavenging ability was 0.9, 1, 2.8, and 3.3%, respectively, and the water ethanol extract (HNE), respectively. The concentration-dependent and statistically significant results were found to be 5.6, 7.5, 8.4, and 15.1%. The water ethanol extract (HNE) was relatively higher in DPPH radical scavenging ability than the water methanol extract (HNM) (Table 2). ).
DPPH RSA (%)
DPPH RSA (%)
모든 결과의 수치는 세 번의 실험값의 평균±SD 임.The numerical values of all results are the mean ± SD of the three experimental values.
<실험 예 6> <Experimental Example 6> MTTMTT reductionreduction assayassay
수질 메탄올 추출물(HNM)이 B16-F10 멜라노마 세포주의 세포증식에 영향을 미치는지 알아보기 위하여 세포독성효과를 알아보았다. The cytotoxic effect of water methanol extract (HNM) on cell proliferation of B16-F10 melanoma cell line was investigated.
B16-F10 멜라노마 세포주에 대한 수질 메탄올 추출물(HNM)의 MTT reduction assay로 세포생존율을 측정하였다. B16-F10 멜라노마 세포주를 96-well plate에 5×104 cells/mL의 농도로 100 μL씩 분주하여 24시간 동안 37℃, 5% CO2 incubator에서 배양한 후, 수질 메탄올 추출물(HNM)을 각각 1, 5, 10, 50 μg/mL의 농도로 제조하여 세포에 처리하고 24시간 동안 배양하였다. 그 후 각 well에 PBS 완충액에 녹인 MTT (5 mg/mL) 용액을 10 mL씩 첨가하고 30분 동안 반응시켜 formazan 형성을 확인한 후, 배지를 완전히 제거하고 well 바닥에 형성된 formazan을 녹이기 위해 100 μL의 DMSO를 첨가하여 ELISA reader(Model 680, Bio Rad, USA)로 540 nm에서 흡광도를 측정하였다. 수질추출물을 처리하지 않고 배양시킨 대조군 세포를 100%로 하였을 때의 상대적인 세포생존율을 구하였다.Cell viability was measured by MTT reduction assay of water methanol extract (HNM) on B16-F10 melanoma cell line. 100 μL of B16-F10 melanoma cell line was injected into 96-well plate at a concentration of 5 × 10 4 cells / mL and incubated in 37 ° C., 5% CO 2 incubator for 24 hours, followed by water methanol extract (HNM). Prepared at concentrations of 1, 5, 10 and 50 μg / mL, respectively, the cells were treated and incubated for 24 hours. Then, 10 mL of MTT (5 mg / mL) solution dissolved in PBS buffer was added to each well and reacted for 30 minutes to confirm formazan formation. Then, 100 μL of the medium was completely removed to dissolve the formazan formed at the bottom of the well. The absorbance was measured at 540 nm with the addition of DMSO using an ELISA reader (Model 680, Bio Rad, USA). Relative cell viability was obtained when 100% of control cells cultured without water extract were treated.
메탄올 추출물 1 μg/mL처리군에서 101.4%, 5 μg/mL처리군에서 99.8%, 10 μg/mL처리군에서 102.0%, 50 μg/mL처리군에서 108.8%로 높은 세포생존율을 나타내었다. 수질추출물은 세포독성을 나타내지 않는다는 것을 확인할 수 있었다(도 3A).Methanol extract showed high cell viability of 101.4% in 1 μg / mL treatment group, 99.8% in 5 μg / mL treatment group, 102.0% in 10 μg / mL treatment group and 108.8% in 50 μg / mL treatment group. It was confirmed that the water extract did not exhibit cytotoxicity (FIG. 3A).
<실험 예 7> Experimental Example 7 LDHLDH releaserelease assayassay
B16-F10 멜라노마 세포주에 대한 수질 메탄올 추출물(HNM)의 세포독성을 측정하기 위해 LDH release assay를 실시하였다. B16-F10 멜라노마 세포주를 96-well plate에 5x104 cells/mL의 농도로 100 μL씩 분주하여 24시간 동안 37℃, 5% CO2 incubator에서 배양한 후, 수질 메탄올 추출물(HNM)을 각각 1, 5, 10, 50 μg/mL의 농도로 B16-F10 멜라노마 세포주에 처리하고 24시간 동안 배양하였다. 배양액의 상층 부분을 새로운 96-well plate에 50 μL씩 분주하고, LDH reagent를 50 μL씩 첨가하여 상온에서 정치시킨 후, 20분간 반응을 시켰다. 색의 변화로 반응이 완료되는 것을 확인한 후 stop solution을 100 μL씩 첨가하여 반응을 중지시키고 ELISA reader로 540 nm에서 흡광도를 측정하여 LDH의 방출량을 측정하였다.LDH release assay was performed to determine the cytotoxicity of the water methanol extract (HNM) against B16-F10 melanoma cell line. 100 μL of B16-F10 melanoma cell lines were injected into 96-well plates at a concentration of 5x10 4 cells / mL, and incubated in 37 ° C., 5% CO 2 incubator for 24 hours. , B16-F10 melanoma cell line at a concentration of 5, 10, 50 μg / mL and incubated for 24 hours. 50 μL of the upper portion of the culture solution was dispensed into a new 96-well plate, 50 μL of LDH reagent was added thereto, and allowed to stand at room temperature, followed by reaction for 20 minutes. After confirming that the reaction was completed by the change of color, the stop solution was added by 100 μL each to stop the reaction, and the absorbance at 540 nm was measured by ELISA reader to measure the amount of LDH emission.
세포 내의 LDH를 측정하기 위해서는 배양액을 제거한 후, 0.5% Triton X-100용액을 50 μL씩 첨가하여 10분 동안 shaking을 하여 세포벽을 제거하고 LDH reagent를 50 μL씩 첨가하여 반응을 시켰고, 반응이 끝나면 stop solution을 넣은 뒤, 540 nm에서 흡광도를 측정하였다. LDH에 대한 세포독성의 백분율은 배양액과 세포 내에서 유리된 총 LDH에 대한 배양액으로부터 유리된 LDH의 값을 수질 메탄올 추출물(HNM)을 처리하지 않은 대조군의 값에 대한 백분율로 계산하였다.To measure the LDH in the cells, remove the culture medium, add 50 μL of 0.5% Triton X-100 solution, shake for 10 minutes, remove the cell wall, and react with 50 μL of LDH reagent. After the stop solution was added, the absorbance at 540 nm was measured. The percentage of cytotoxicity against LDH was calculated as the percentage of LDH liberated from the culture against the total LDH liberated in culture and cells as a percentage of the value of the control that was not treated with aqueous methanol extract (HNM).
도 3B와 같이 수질 메탄올 추출물(HNM)을 1, 5, 10, 50 μg/mL의 농도로 각각 처리한 결과, 각각 LDH 방출량이19.4%, 18.8%, 19.1%, 23.3%로서 무처리 대조군(20.4%)과 거의 차이가 없으며, 세포독성을 나타내지 않는다는 것을 확인할 수 있었다. As shown in FIG. 3B, the aqueous methanol extract (HNM) was treated at concentrations of 1, 5, 10, and 50 μg / mL, respectively. As a result, LDH emissions were 19.4%, 18.8%, 19.1%, and 23.3%, respectively. %), And showed no cytotoxicity.
<실험 예 8> B16-F10 Experimental Example 8 B16-F10 멜라노마Melanoma 세포주의 형태학적 변화 관찰 Observing Morphological Changes in Cell Lines
멜라닌 세포는 수지상 돌기를 통하여 인접한 각질형성 세포와 연결하여 표피-멜라닌 단위(epidermal melanin unit)를 형성하는데, 이는 멜라노좀의 수송에 중요한 역할을 하고 있다. 수질 메탄올 추출물(HNM)의 수지상 돌기의 변화와 세포사멸에 대한 영향을 확인하기 위하여 inverted microscope를 이용하여 B16-F10 멜라노마 세포주의 형태학적 변화를 관찰하였다. Melanocytes connect with adjacent keratinocytes through dendritic processes to form epidermal melanin units, which play an important role in the transport of melanosomes. Morphological changes of B16-F10 melanoma cell lines were observed using an inverted microscope to investigate the effects of water methanolic extract (HNM) on dendritic processes and apoptosis.
B16-F10 멜라노마 세포주를 6-well plate에 5x104 cells/mL이 되도록 2 mL씩 첨가한 후 24시간 동안 배양하고, 수질 메탄올 추출물(HNM)을 각각 5, 10, 50 μg/mL의 농도로 처리하고, 대조군의 경우에는 1% 메탄올이 되도록 처리한 후 24시간 배양하여 관찰하였다. 위상차현미경(Phase contrast microscope) (Nikon, Tokyo, Japan)을 이용하여 형태학적 특징을 100배로 사진 촬영하였다.Add 2 mL of B16-F10 melanoma cell line to 5x10 4 cells / mL in a 6-well plate, incubate for 24 hours, and incubate the aqueous methanol extract (HNM) at concentrations of 5, 10 and 50 μg / mL, respectively. Treatment, and in the case of the control was treated to 1% methanol and observed by culturing for 24 hours. Morphological features were photographed 100 times using a phase contrast microscope (Nikon, Tokyo, Japan).
그 결과, 무처리한 대조군과 수질 메탄올 추출물(HNM)을 각각 5, 10, 50 μg/mL의 농도로 각각 처리한 군을 비교하였을 때, 세포의 조밀한 정도와 형태학적인 차이가 없다는 것을 확인할 수 있었다(도 4). As a result, when comparing the untreated control and the group treated with water methanol extract (HNM) at concentrations of 5, 10, and 50 μg / mL, respectively, it was confirmed that there was no difference in the density and morphological difference of the cells. (FIG. 4).
<실험 예 9> Experimental Example 9 HoechstHoechst 33342 염색 33342 dye
세포독성효과의 기전연구를 위해 B16-F10 멜라노마 세포주의 apoptosis 활성여부를 확인하였다. Apoptosis의 형태학적 특징 중의 하나인 핵의 변화를 관찰하기 위해서 핵 내 DNA에 특이적으로 결합하는 형광염색제인 hoechst 33342를 사용하여 핵을 염색하고 형광현미경으로 관찰하였다. To study the mechanism of cytotoxic effect, we confirmed whether apoptosis activity of B16-F10 melanoma cell line was active. In order to observe the change of the nucleus, one of the morphological characteristics of apoptosis, the nucleus was stained using a fluorescent dye, hoechst 33342, which specifically binds to DNA in the nucleus, and observed under a fluorescence microscope.
세포를 6-well plate에 5x104 cells/mL로 24시간 동안 배양하여 수질 메탄올 추출물(HNM)을 각각 5, 10, 50 μg/mL의 농도로 처리하고 대조군의 경우 메탄올을 1%가 되도록 처리하여 24시간 배양 시킨 후, PBS 완충액으로 2회 세척하고 10% formalin으로 고정한 후, hoechst 33342 (10 μM)로 염색하여 형광현미경 하에서 400배로 핵을 관찰하였다.Cells were incubated for 24 hours at 5x10 4 cells / mL in a 6-well plate and treated with methanol extracts (HNM) at concentrations of 5, 10, and 50 μg / mL, respectively. After incubation for 24 hours, washed twice with PBS buffer, fixed with 10% formalin, stained with hoechst 33342 (10 μM) and observed the nucleus 400 times under a fluorescence microscope.
도 5에서 보이는 바와 같이, 무처리 대조군의 세포핵은 타원형의 온전한 핵 모양을 나타내며, 수질 메탄올 추출물(HNM)을 5, 10, 50 μg/mL로 처리한 실험군의 세포핵 역시 타원형의 온전한 핵 모양을 유지하였다. As shown in FIG. 5, the cell nucleus of the untreated control group showed an oval intact nucleus shape, and the cell nucleus of the experimental group treated with 5, 10, and 50 μg / mL of water methanol extract (HNM) also maintained an oval intact nucleus shape. It was.
실험 예 6 내지 9의 결과는 수질추출물이 세포에 대한 독성이 없다는 것을 보여주는 것이다.The results of Experimental Examples 6 to 9 show that the water extract is not toxic to cells.
이하, 본 발명의 제형의 일구현예를 예시하나, 이제 한정되는 것은 아니다.Hereinafter, one embodiment of the formulation of the present invention is illustrated, but is not limited thereto.
<제형 예 1> 수질추출물을 포함하는 영양크림의 제조<Formulation Example 1> Preparation of nutrition cream containing water extract
수질 메탄올 추출물 0.5중량%, 프로릴렌글리콜 6 중량%, 글리세린 4중량%, 유동파라핀 5중량%, 스쿠알렌 3중량%, 폴리솔베이트60 1.5 중량% 및 정제수 잔량을 혼합하여, 통상적인 방법에 따라 영양크림을 제조하였다.0.5% by weight of water methanol extract, 6% by weight of proylene glycol, 4% by weight of glycerin, 5% by weight of liquid paraffin, 3% by weight of squalene, 1.5% by weight of
<제형 예 2> 연고제<Formulation Example 2> Ointment
수질 메탄올 추출물 1 g, 덱스판테놀 1.5 g, 스테아린산 1.0 g, 유동파라핀 5.0 g, 경납 4.0 g, 세탄올 3.0 g, 프로필렌글리콜 13.0 g, 트리에탄올아민 1.5 g, 디부틸하이드록시톨루엔 0.025 g, 안식향산프로필 0.015 g, 폴리소르베이트 800.1 g, 정제수 63.0 g의 조성의 성분들을 통상의 연고제 제조방법에 따라 배합하여 연고제를 제조하였다.Water methanol extract 1 g, dexpanthenol 1.5 g, stearic acid 1.0 g, liquid paraffin 5.0 g, braze 4.0 g, cetanol 3.0 g, propylene glycol 13.0 g, triethanolamine 1.5 g, dibutylhydroxytoluene 0.025 g, propyl benzoate 0.015 g, polysorbate 800.1 g, purified water 63.0 g of the composition of the composition according to the conventional ointment preparation method to prepare an ointment.
<제형 예 3> 음료<Formulation Example 3> Drink
수질 메탄올 추출물 9중량%, 과당 10 중량 %, 정백당 1 중량%, 구연산나트륨 0.2 중량%에 정제수를 총 100 중량% 되도록 배합하고 교반하여 통상의 음료제조 방법으로 제조하였다.9% by weight of the water methanol extract, 10% by weight fructose, 1% by weight per white sugar, 0.2% by weight of sodium citrate was added to a total of 100% by weight of purified water and stirred to prepare a conventional beverage production method.
Claims (12)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120017568A KR101376197B1 (en) | 2012-02-21 | 2012-02-21 | Composition comprising extract of Hirudo nipponica Whitman for inhibiting synthesis of melanin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020120017568A KR101376197B1 (en) | 2012-02-21 | 2012-02-21 | Composition comprising extract of Hirudo nipponica Whitman for inhibiting synthesis of melanin |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20130096055A true KR20130096055A (en) | 2013-08-29 |
KR101376197B1 KR101376197B1 (en) | 2014-03-20 |
Family
ID=49219119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020120017568A KR101376197B1 (en) | 2012-02-21 | 2012-02-21 | Composition comprising extract of Hirudo nipponica Whitman for inhibiting synthesis of melanin |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR101376197B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107519036A (en) * | 2017-09-06 | 2017-12-29 | 深圳肽之妃科技有限公司 | A kind of striae of pregnancy spray containing polypeptide and preparation method thereof |
-
2012
- 2012-02-21 KR KR1020120017568A patent/KR101376197B1/en active IP Right Grant
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107519036A (en) * | 2017-09-06 | 2017-12-29 | 深圳肽之妃科技有限公司 | A kind of striae of pregnancy spray containing polypeptide and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
KR101376197B1 (en) | 2014-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR102186872B1 (en) | Skin whitening composition comprising milk exosomes | |
WO2023113111A1 (en) | Skin whitening composition for relieving melasma, age spots, etc. using water-soluble mastic gum | |
KR20210108911A (en) | A composition for antioxidant or whitening compriging rosemary ionic liquid extract | |
KR101721022B1 (en) | Composition for comprising adipic acid for improving skin wrinkle or enhancing skin elasticity | |
KR101935492B1 (en) | Composition comprising yarayara for preventing hair loss or stimulating hair growth | |
KR101376197B1 (en) | Composition comprising extract of Hirudo nipponica Whitman for inhibiting synthesis of melanin | |
JP2013032366A (en) | Sebum amount decrease inhibitor containing alpha-glycosyl hesperidin for use in oral administration/ingestion | |
KR20150087141A (en) | Composition for improving skin | |
KR20100028202A (en) | Composition having skin whitening activity comprising an extract of buddleja officinalis | |
KR20190077156A (en) | Cosmetic composition for skin whitening and moisturizing comprising larva extract of Protaetia brevitarsis as effective component | |
KR20160020253A (en) | Cosmetic or pharmaceutical composition for skin whitening, elasticity, anti-wrinkle, or skin moisturizing comprising atractylenolide I | |
KR101551106B1 (en) | A composition comprising the extract of Paspalum thunbergii Kunth | |
KR100755742B1 (en) | Skin whitening composition containing acrylate type compound | |
KR20060101100A (en) | Rose extract having skin whitening effect | |
KR102089209B1 (en) | Composition for skin whitening comprising guaiacol, phytol and cavacrol as active ingredients | |
KR100596316B1 (en) | Composition of health functional food to support skin beauty and antiaging | |
KR20230033388A (en) | Compositions for Improving Skin Wrinkles and Skin Whitening Using an Extract of Veratrum versicolor | |
KR20210134589A (en) | Composition for improving skin comprising an extract of Pueraria thomsonii or a compound derived therefrom | |
KR102010171B1 (en) | Composition for skin whitening comprising 5-iodotubercidin | |
KR20210131598A (en) | Composition for preventing hair loss or promoting hair growth, comprising Camellia japonica pericarp extract as an active ingredient | |
KR101995384B1 (en) | Composition for skin whitening and anti-oxidation comprising fermented Gynura procumbens as effective component | |
JP4902967B2 (en) | Melanin production inhibitor | |
KR101526435B1 (en) | Compositions for skin-whitening comprising extract of Vitis amurensis ruprecht | |
KR102683218B1 (en) | Composition for whitening comprising natural products derived extracellular vesicles | |
KR102567263B1 (en) | Composition for preventing, treating or improving metabolic diseases containing essential oil mixture of Mentha haplocalyx, Citrus unshiu peel and Coicis Semen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20170307 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20180322 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20190916 Year of fee payment: 6 |